REG - Futura Medical PLC - Notice of Pain Relief Portfolio Study Results <Origin Href="QuoteRef">FUM.L</Origin>

Futura MedicalAnnouncement

16/07/2015 15:02

RNS Number : 7977S
Futura Medical PLC
13 July 2015
 For immediate release
13 July 2015
Futura Medical plc
("Futura" or "the Company")
Notice of Pain Relief Portfolio Study Results
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, intends to announce the headline results from the clinical study of its portfolio of three topical pain relief products on Tuesday 14 July 2015 at 7.00am.
A presentation for analysts will be held at 10.00am on 14 July 2015 at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN, to discuss the results of the study. 
For further information please contact:
Futura Medical plc

James Barder, Chief Executive
Tel: +44 (0) 1483 685 670
Email to: james.barder@futuramedical.com
www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Tom Smale - Corporate Finance 
Tel:+44 (0) 20 7496 3000
For media enquiries please contact: 

Buchanan 

Mark Court / Sophie Cowles / Stephanie Watson
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCSFAFISFISEIW